Specific protection against breast cancers by cyclin D1 ablation. - Wikidata - wikimedia - TriplyDB

Specific protection against breast cancers by cyclin D1 ablation.

Specific protection against breast cancers by cyclin D1 ablation.

http://www.wikidata.org/entity/Q34082446

about

Evidence that SOX2 overexpression is oncogenic in the lung Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc Cyclin D1 down-regulation is essential for DBC2's tumor suppressor function Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?The prolyl isomerase Pin1 in breast development and cancer Proteotypic classification of spontaneous and transgenic mammary neoplasms Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models Wnt1 is epistatic to Id2 in inducing mammary hyperplasia, ductal side-branching, and tumors in the mouse Cyclins in breast cancer: too much of a good thing.IkB kinase alpha: a link in the chain of the mammary cycle.Mammary epithelial cell transformation: insights from cell culture and mouse models.Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.Targeting the Checkpoint to Kill Cancer Cells Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing Oncogenic Kras initiates leukemia in hematopoietic stem cells D-type Cyclins are important downstream effectors of cytokine signaling that regulate the proliferation of normal and neoplastic mammary epithelial cells.Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

P2860

Q21091126-47B63A9D-CE3A-4ABF-9D2C-23183E75F05C Q21195209-06C603C6-4057-4CDC-BD4A-22148DBB7499 Q21195212-0B64DE5D-BE21-4E08-914B-26720A0B1037 Q21245733-75E2D0EC-B7F2-419D-A78B-81FF1FBBC9C2 Q24297959-A09F6372-9252-4DEC-94A3-1169D9ED2BCE Q24303568-F607A210-2C20-414F-9654-678CC8189CCC Q24309520-C25B80F1-B0DD-446E-BC38-7F2C85EF3AD8 Q24316318-1E693B8B-441D-4A20-AAC8-469ED98F8880 Q24337518-9A436B7C-7805-487E-B46C-75DA947B7E8A Q24534882-BCE347D9-95B5-4429-8D87-7AF3BA27A730 Q24537644-7E5AEBBD-6E99-4564-B06D-CA53882C6852 Q24554383-EDBEA784-2453-4EF5-9AAE-51201601AFFB Q24555051-E45E2E79-B524-482B-A220-06CD937BD8F1 Q24561962-FE9F0820-8E14-4A1C-80A5-9A1865F17640 Q24608910-2375A263-984E-4C50-9E69-982E5B64A89B Q24610494-A3F2BB6F-DE11-427A-9E99-D2BBC3144FF3 Q24616764-505599DD-E165-4CC7-AC7C-7634B855C48E Q24622802-B1ACB994-682B-43E9-BE10-B1C9EFFECBC0 Q24653031-92824BFB-6EAA-433A-AF6F-758D621B7FD9 Q24683644-9C58DA15-63C6-4D86-AB26-EC648E54E8F9 Q24684054-9AD1DD56-DDFE-4BAB-B783-142A3C5F7F3C Q24746253-EA0B7909-8F45-4223-B5CF-44BFBA38D258 Q24794064-DDD01CB2-1523-431A-9F15-1B7059AE9916 Q24795560-412F57C5-CA54-4B2B-ACA3-13BEA23676BF Q24795869-CFC02711-74A0-49B6-A5E7-42D129822020 Q24796232-3611AB1D-9DE5-4AB9-9AC6-DC163F0B2425 Q24799888-FB5E0DCD-BDB3-49D8-BF1E-ECF970EFB558 Q24802591-A1199EBE-AA15-446A-A553-C32C69676B69 Q24802711-768004CB-1179-4B51-A070-85B55BB86C8A Q24810846-92F93478-8FE6-4F8C-B37E-6706F20CE5B5 Q25257349-CB3E90D7-A865-433B-8590-5E3152C2C995 Q26795781-B2AF1D37-E5D4-46B8-BAC5-B1113992F293 Q26799290-9D4FDB38-E5BC-4AA4-AD63-5454D4770B1D Q27022834-7F029FFC-7EE7-49EA-B5FC-B97353C480C2 Q27302884-501E5772-B2FE-4665-8D47-612737FF6769 Q27322637-56C4BC8E-EBFF-49D6-9E7E-B8363E6B40BD Q27331698-7EECEB31-FF8C-43AB-96F0-7A215653AA86 Q27690967-623CC806-B4EE-4C9E-85C3-8B25E0D943F5 Q27851564-B708E836-6203-4FC8-AE74-59AD1D343935 Q28069910-DC871993-22FA-4165-94CF-1DF109FD609E

P2860

Specific protection against breast cancers by cyclin D1 ablation.

http://www.wikidata.org/entity/Q34082446

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Specific protection against breast cancers by cyclin D1 ablation.

@ast

Specific protection against breast cancers by cyclin D1 ablation.

@en

Specific protection against breast cancers by cyclin D1 ablation.

@nl

type

label

Specific protection against breast cancers by cyclin D1 ablation.

@ast

Specific protection against breast cancers by cyclin D1 ablation.

@en

Specific protection against breast cancers by cyclin D1 ablation.

@nl

prefLabel

Specific protection against breast cancers by cyclin D1 ablation.

@ast

Specific protection against breast cancers by cyclin D1 ablation.

@en

Specific protection against breast cancers by cyclin D1 ablation.

@nl

P1433

Q34082446-A69703F0-B5B7-41A7-9E77-3EE4850E43F7

P1476

Q34082446-C9352982-5B0C-442B-AE09-CC864DC8F677

P2093

Q34082446-262B19F3-DCF0-4F0D-90FC-EF34263554C1

Q34082446-B3EAFF7E-B67E-4EED-AE19-BFF3BD69D43A

Q34082446-F0141468-9722-41A7-81BD-52417DE13023

P2860

Q34082446-02E76A76-69F1-4557-A54A-3A9278B3F0FB

Q34082446-045C5041-3BDA-4375-B1C0-FBA2B20A5AD0

Q34082446-09539AC9-13E4-4811-835B-3C9215751D04

Q34082446-0CB05926-5E82-4C64-88C1-3B0791A7B038

Q34082446-3517E87A-E67C-497F-AEC1-CA3EB845F443

Q34082446-420231D3-3666-4C2A-A2C8-EFF8A61BFB69

Q34082446-4BF11AD6-DB8C-4F54-BA4B-0732D62AE6EE

Q34082446-5DE93CB5-B2CD-4905-A4EC-0F817F437EAA

Q34082446-601342CD-C358-4040-9FF9-C71C9B99BA05

Q34082446-62EB81B1-289D-4CDE-9D50-36B4D63A63AD

P2888

Q34082446-DD4634CE-49C9-4B1D-8A48-8F32A20DA59F

P304

Q34082446-5E80D0D7-188A-45CF-AB2E-FE3D42A653C9

P31

Q34082446-3372E6A7-6B18-4B8B-9430-6A5204435A1B

P356

Q34082446-3C72B8D2-4592-406E-929F-80B7E3A2C1E6

P407

Q34082446-6A4DDF03-20FD-4119-9425-3E6FEBA3CC6E

P433

Q34082446-E8217422-C035-41AD-BB92-279F5A9FD6F9

P478

Q34082446-A4CF6E81-5595-4B4F-82D8-1848ED0FECE9

P577

Q34082446-8C3D19AE-5AB9-4395-89D1-A8F925717BA5

P5875

Q34082446-A84AE4C2-B237-45BC-B788-17505F25AE52

P6179

Q34082446-37E5EDB9-89E6-49B3-91AD-D751D9E39758

P698

Q34082446-3B830894-4F80-4004-B45E-AF0725CB9A12

P356

P1433

P1476

Specific protection against breast cancers by cyclin D1 ablation.

@en

P2093

Geng Y

http://www.w3.org/2001/XMLSchema#string

Sicinski P

http://www.w3.org/2001/XMLSchema#string

Yu Q

http://www.w3.org/2001/XMLSchema#string

P2860

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

CDK inhibitors: positive and negative regulators of G1-phase progression

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.

Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.

Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.

Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.

Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis.

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo

P2888

P304

1017-1021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/35082500

http://www.w3.org/2001/XMLSchema#string

P407

P433

6841

http://www.w3.org/2001/XMLSchema#string

P478

411

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11910396

http://www.w3.org/2001/XMLSchema#string

P6179

1034302480

http://www.w3.org/2001/XMLSchema#string

P698

11429595

http://www.w3.org/2001/XMLSchema#string